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Abstract
Background: Organotins are highly toxic and widely distributed environmental chemicals. Dibutyltin (DBT) is used as
stabilizer in the production of polyvinyl chloride plastics, and it is also the major metabolite formed from tributyltin (TBT) in
vivo. DBT is immunotoxic, however, the responsible targets remain to be defined. Due to the importance of glucocorticoids
in immune-modulation, we investigated whether DBT could interfere with glucocorticoid receptor (GR) function.
Methodology: We used HEK-293 cells transiently transfected with human GR as well as rat H4IIE hepatoma cells and native
human macrophages and human THP-1 macrophages expressing endogenous receptor to study organotin effects on GR
function. Docking of organotins was used to investigate the binding mechanism.
Principal Findings: We found that nanomolar concentrations of DBT, but not other organotins tested, inhibit ligand binding
to GR and its transcriptional activity. Docking analysis indicated that DBT inhibits GR activation allosterically by inserting into
a site close to the steroid-binding pocket, which disrupts a key interaction between the A-ring of the glucocorticoid and the
GR. DBT inhibited glucocorticoid-induced expression of phosphoenolpyruvate carboxykinase (PEPCK) and tyrosine-
aminotransferase (TAT) and abolished the glucocorticoid-mediated transrepression of TNF-a-induced NF-kB activity.
Moreover, DBT abrogated the glucocorticoid-mediated suppression of interleukin-6 (IL-6) and TNF-a production in
lipopolysaccharide (LPS)-stimulated native human macrophages and human THP-1 macrophages.
Conclusions: DBT inhibits ligand binding to GR and subsequent activation of the receptor. By blocking GR activation, DBT
may disturb metabolic functions and modulation of the immune system, providing an explanation for some of the toxic
effects of this organotin.
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Introduction
Organotins are among the most toxic and widely distributed
environmental chemicals. The most abundant organotin in the
environmentistributyltin(TBT),amolluscicideandfungicidewidely
used as an antifouling paint for boat and fish nets and that thus is
dispersed into the marine environment [1,2]. TBT interferes with
reproduction in marine animals, inducing imposex (superimposition
of male sexual characters in females) in gastropod molluscs, an effect
used to measure TBT pollution in sea-water [3,4]. TBT concentra-
tions ranging from 4–323 nM were measured in blood samples from
healthy human subjects [5]. In mammals, organotins are hepato-
toxic, neurotoxic and immunotoxic. At doses comparable with those
found in human blood, TBT promotes Th2 cell polarization and
exacerbates airway inflammation, providing a possible mechanism
for enhanced susceptibility to allergic diseases [6]. Thus, TBT
contamination represents a serious health problem and the great
concern about the toxicity of TBT is underlined by recent
negotiations of the United Nations’ International Maritime
Organization for a global ban in the use of TBT.
In vivo, TBT is mainly metabolized to DBT in the liver,
involving cytochrome P450 enzymes [7,8]. DBT, itself, is used in
the production of polyvinyl chloride (PVC) plastic tubes and
bottles [9], and humans are exposed to DBT by direct uptake from
drinking water due to leaching from PVC water distribution pipes
[10]. DBT is considered to be highly neurotoxic and immunotoxic
[5,11,12], and concentrations ranging from 11–401 nM were
measured in human blood [5]. Hence, DBT needs to be
considered as a potential toxic chemical. Both TBT and DBT
cause thymus involution by inhibiting the proliferation of
immature CD4
2/CD8
+ thymocytes, but at high concentrations,
they induce thymocyte apoptosis [13]. The immunotoxic effects of
DBT are more rapid and more pronounced than those of TBT,
raising the possibility that some effects of TBT are primarily
PLoS ONE | www.plosone.org 1 October 2008 | Volume 3 | Issue 10 | e3545caused by its metabolite DBT [14]. The target(s) for the
immunotoxic actions of DBT have not been determined.
We hypothesize that DBT affects one or more glucocorticoid
responses because this steroid has important actions on the
immune system [15,16]. Despite the importance of glucocorticoids
in the regulation of immune functions, only few studies
investigated the potential interference of environmental pollutants
with glucocorticoid-mediated responses [17]. None of these studies
investigated DBT as a disruptor of the immune response.
With the goal of elucidating the immunotoxic mechanism of
DBT and other organotins, we investigated their potential
interference with glucocorticoid action using cells expressing
recombinant GR, as well as macrophages expressing endogenous
GR. We found that DBT, in contrast to TBT, diphenyltin (DPT)
and triphenyltin (TPT), inhibits dexamethasone binding to GR
and blocks receptor activation. We then used docking software
[18,19] to study the binding of these chemicals to the GR and
provide evidence that DBT, but not the other organotins, disrupts
an essential interaction between the A-ring on dexamethasone and
the GR by binding to an allosteric site.
Results
Dibutyltin, but not other organotins tested, inhibits the
transcriptional activity of GR
To investigate whether organotins disrupt GR-dependent
transcriptional regulation, we employed HEK-293 cells transiently
expressing recombinant human GRa and a b-galactosidase
reporter driven by a glucocorticoid-responsive MMTV-promoter.
In the absence of organotins, 100 nM cortisol increased GR-
dependent expression of galactosidase activity 185-fold. HEK-293
cells that were transfected only with the b-galactosidase reporter
showed background activity because HEK-293 cells express no or
very low levels of endogenous GR. Upon simultaneous incubation
of cells with DBT and cortisol, a dose-dependent inhibition of GR-
mediated transactivation was observed (Fig. 1A). At 1 mM DBT,
the inhibition was comparable with that of 1 mM RU486.
Interestingly, the repeated exposure of cells to DBT increased
the inhibitory effect on GR-mediated transactivation. Upon
subjecting cells to eight changes of medium containing a given
DBT concentration at 15 min intervals and preincubation for
another 14 h, a two- to three-fold stronger inhibition of GR
transactivation was observed than in cells that were preincubated
for 16 h with the same DBT concentration (data not shown). In
contrast to DBT, a slight stimulation of transactivation was found
for TBT, reaching a maximal effect at 250 nM (Fig. 1B). Whereas
DPT had no effect on GR-mediated transactivation (Fig. 1C), an
up to two-fold stimulation was observed for TPT, with a 75%
increase of transactivation at 10 nM (Fig. 1D). This stimulation
was reversed at 250–500 nM. At these concentrations, no
cytotoxicity could be detected in the MTT assay. Dimethyltin,
trimethlytin and dioctyltin, up to 1 mM, did not affect GR-
mediated transactivation. Similar results were obtained in
experiments using 10 nM dexamethasone instead of 100 nM
Figure 1. Inhibition of GR-mediated transactivation by organotins. HEK-293 cells transiently expressing pMMTV-LacZ, pCMV-LUC and human
GR-a were simultaneously incubated with 100 nM cortisol and vehicle (CTRL), various concentrations of dibutyltin (DBT) (A), tributyltin (TBT) (B),
diphenyltin (DPT) (C), triphenyltin (TPT) (D)o r1mM of RU486 (RU). After incubation for 20 h, galactosidase reporter activity, normalized to the internal
luciferase control, was determined. Data (mean6SD from four independent experiments) represent percentage relative to the control at 100 nM
cortisol in the absence of inhibitors. *p,0.05.
doi:10.1371/journal.pone.0003545.g001
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transactivation in the absence of glucocorticoids (data not shown).
Dibutyltin blocks ligand binding to GR
To assess whether DBT inhibits GR function by directly
interfering with ligand binding, HEK-293 cells were simulta-
neously incubated with radiolabeled [
3H]-dexamethasone and
various concentrations of DBT. A dose-dependent decrease of
dexamethasone binding to GR was observed, with approximately
50% inhibition of binding upon incubation with 150 nM DBT
(Fig. 2A). Addition of unlabeled dexamethasone revealed a typical
displacement pattern of tritiated dexamethasone in the presence or
absence of DBT (Fig. 2B,C). A more pronounced inhibitory effect
by DBT on dexamethasone binding to GR was obtained after
preincubating cells overnight with DBT-containing medium, with
an IC50 of about 50 nM (Fig. 2C). To determine if the reduced
dexamethasone binding to GR upon preincubation with DBT was
due to decreased GR protein expression, we performed Western
blotting of extracts from cells expressing GR and preincubated
with either vehicle or DBT. Incubation with DBT for either 3 h or
16 h did not alter GR expression relative to the actin control
(Fig. 2D), suggesting that DBT did not affect the number of
receptor complexes but decreased glucocorticoid binding affinity.
Thus, inhibition of glucocorticoid binding to GR in the presence
of DBT provides an explanation for the reduced transactivation of
the b-galactosidase reporter.
DBT disrupts glucocorticoid-dependent target gene
regulation in liver cells
The observation that DBT blocked GR activation in an
overexpression cell system led us to test whether the disruption
of GR activation could be observed in cells expressing endogenous
receptor. Incubation of rat H4IIE hepatoma cells, a widely used
liver cell model, with 10 nM dexamethasone for 24 h resulted in
elevated PEPCKmRNA expression approximately 6-fold (Fig. 3A).
This glucocorticoid-induced stimulation of PEPCK mRNA
expression was diminished in a dose-dependent manner when
cells were preincubated for 16 h with DBT. The effect of
glucocorticoids was almost completely abolished in the presence
of 500 nM DBT.
Figure 2. Inhibition of ligand binding to GR by dibutyltin. HEK-293 cells were transfected with a plasmid for human GR-a, followed by
overnight incubation in serum-free medium containing vehicle (0.1% DMSO)(A,B) or in medium containing either vehicle or 50 nM or 100 nM DBT (C).
Cells were then incubated for 3 h with 10 nM radiolabeled dexamethasone and various concentrations of DBT (A) or with 10 nM radiolabeled
dexamethasone, various concentrations of unlabeled dexamethasone and various concentrations of DBT (B,C) prior to removal of unbound steroids
and determination of bound dexamethasone by scintillation counting (A). Data represent mean6SD from three independent experiments. D, cells
transiently expressing GR-a were preincubated for 16 h in serum-free medium containing vehicle (0.1% DMSO), 10 nM dexamethasone (Dex) or
500 nM DBT, followed by incubation for another 3 h with vehicle, 10 nM dexamethasone or 500 nM DBT and 10 nM dexamethasone, respectively
(lane 1–3). Alternatively, cells preincubated for 16 h in serum-free medium were incubated for 3 h in medium containing 500 nM DBT and 10 nM
dexamethasone (lane 4). Cells were lysed and the expression of GR protein and actin control was analyzed by Western blotting.
doi:10.1371/journal.pone.0003545.g002
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PLoS ONE | www.plosone.org 3 October 2008 | Volume 3 | Issue 10 | e3545As a second marker of GR activation, we measured the effect of
DBT on TAT activity. Incubation with 5 nM dexamethasone
increased TAT activity approximately 6-fold in H4IIE hepatoma
cells. (Fig. 3B). Treatment of cells with DBT dose-dependently
diminished the dexamethasone-induced stimulation of TAT
activity. GR antagonist RU486 (1 mM) was used as a control.
DBT had no effect on basal TAT activity in the absence of
glucocorticoids (data not shown).
DBT impairs glucocorticoid-mediated suppression of
cytokine production in macrophages
Exposure of macrophages to LPS strongly induces production of
various pro-inflammatory cytokines. Among them, TNF-a and IL-
6 play a pivotal role in the inflammatory response. The anti-
inflammatory effect of glucocorticoids is at least in part due to the
modulation of cytokine-production in a GR-dependent manner.
To assess potential interference of DBT with glucocorticoid-
dependent suppression of pro-inflammatory cytokines, native
human monocytes were differentiated into macrophages. Macro-
phages were then preincubated for 16 h with vehicle or DBT,
followed by simultaneous addition of LPS and 10 nM dexameth-
asone and incubation for another 20 h. Detection by ELISA
revealed a DBT dose-dependent abrogation of the dexametha-
sone-mediated suppression of TNF-a and IL-6 production after
LPS-induced stimulation (Fig. 4A). At 500 nM the effect of DBT
was comparable with that of 1 mM RU486. DBT alone had no
effect on IL-6 or TNF-a production (not shown). Similar results
were observed in experiments with THP-1 cells that were
differentiated into macrophages by treatment with PMA (Fig. 4B).
Dibutyltin inhibits GR-mediated trans-repression of NF-
kB
Trans-repression of NF-kB activity by GR is important for the
anti-inflammatory action of glucocorticoids. Therefore, we tested
whether DBT might reverse glucocorticoid-dependent inhibition
of NF-kB activation upon incubation with TNF-a. TNF-a strongly
stimulated the expression of a luciferase reporter gene driven by
the MHC promoter containing three NF-kB binding sites, an
effect which was suppressed by dexamethasone (Fig. 5). As for the
cytokine production, the glucocorticoid-mediated suppression of
NF-kB activation was inhibited in a dose-dependent manner by
DBT or by RU486.
Docking of organotins into human GR
To study the mechanism by which DBT inhibits dexametha-
sone binding to GR, we used Autodock 4 [18,19] to screen the GR
3D-structure [21] for binding sites for DBT and other organotins.
We identified two binding sites for DBT, DPT and TPT and one
site for TBT (Fig. 6). These are the steroid-binding site and a site
that is adjacent to the steroid-binding site [21]. Differences in the
relative occupancy for each organotin in the GR are summarized
in Table 1. The dexamethasone binding site was the primary
binding site in the GR for all organotins. Occupancy of the
steroid-binding site varied from 51% for TPT to 100% for TBT.
In docking earch organotin into the GR, Autodock provides a
summation of the van der Waals, hydrogen bond and desolvation
energies (summation binding energy) and a separate calculation of
the electrostatic binding energy. For organotins, the summation
binding energy consists mainly of hydrophobic interactions. In
general, the electrostatic binding energy is about 20% to 25% of
the summation binding energy for the binding of the organotins
into the GR. Thus for DBT, TBT, DPT and TPT in the steroid-
binding site, the summation binding energies are 220.1 kJ/mol,
226.1 kJ/mol, 222.4 kJ/mol and 226.7 kJ/mol, respectively.
DBT, which is the smallest organotin has the weakest summation
binding energy. For DBT, TBT, DPT and TPT the electrostatic
binding energies are 23.6 kJ/mol, 22.5 kJ/mol, 21.5 kJ/mol
and 20.3 kJ/mol, respectively. Interestingly, DBT has the
strongest electrostatic binding energy and TPT has the lowest
electrostatic binding energy in the steroid-binding site.
Figure 3. Inhibition of glucocorticoid-mediated expression of hepatic target genes by dibutyltin. A, DBT prevents glucocorticoid-
induced stimulation of PEPCK mRNA expression. H4IIE hepatoma cells were preincubated for 16 h in the absence or presence of DBT, followed by
adding 10 nM dexamethasone and incubation for another 24 h at 37uC. mRNA levels were determined by real-time RT-PCR using TaqMan
technology. Data (mean6S.D. of triplicates from four independent experiments) are relative to the ratio of PEPCK mRNA to b-actin control mRNA
from cells treated with dexamethasone in the absence of DBT. B, DBT inhibits glucocorticoid-induced stimulation of TAT activity. H4IIE cells were
preincubated for 16 h in the absence or presence of DBT, followed by adding 5 nM dexamethasone and incubation for another 20 h. TAT activity,
determined in cell lysates and normalized to protein content, is given as mean6S.D. of triplicates from four independent experiments and normalized
to the positive control in the presence of dexamethasone. * p,0.05.
doi:10.1371/journal.pone.0003545.g003
Inhibition of GR by Dibutyltin
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binding energies are 218.2 kJ/mol, 222.1 kJ/mol, 228.2 kcal/
mol, respectively. For DBT, DPT and TPT, the electrostatic
binding energies are 25.1 kJ/mol, 24.8 kJ/mol and 25.0 kJ/
mol, respectively.
Organotin docking to the dexamethasone-binding site
Figure 7A shows DBT, TBT, DPT and TPT in the dexameth-
asone-binding site of the GR derived from the structure determined
by Bledsoe et al. [21]. DBT and TBT overlap the region where the
D-ring and C17-side chain of dexamethasone insert into the GR.
Both DBT and TBT are much smaller than dexamethasone, which
reduces interactions of these organotins with the GR. In contrast,
DPT and TPT overlap much of the dexamethasone-binding site in
the GR. In Figure 7A, we show four residues that are important in
stabilizing binding of dexamethasone to the GR [21].
Organotin docking to an allosteric site
DBT, DPT and TPT docked into the GR at an allosteric site,
which is close to the A-ring of dexamethasone (Fig. 7B). Of the
four organotins that we studied, only DBT inhibits transcriptional
activity of GR in the presence of 100 nM cortisol, which indicates
that DBT exerts its inhibitory action by binding to the allosteric
site. To investigate further the interaction of GR with DBT in this
secondary site, we analyzed the interaction of DBT with GR
under two conditions. First, we analyzed DBT in the apo-GR to
simulate DBT binding in the absence of glucocorticoids. Second,
we analyzed DBT in the GR-dexamethasone complex.
For the first analysis, we docked DBT into the GR and minimized
the DBT-GR complex with Discover 3, to allow all of the amino
acids in the GR to relax, so as to diminish unfavorable steric
interactions and optimize favorable interactions between GR and
DBT. Then, we inserted dexamethasone into the minimized
structure and analyzed the interactions between DBT and
dexamethasone with the GR. In this analysis, we focus on the effect
of DBT on the interactions between the C3-ketone on dexameth-
asone and Arg
611 and Gln
570 in the GR because these amino acids
have been shown to be important in stabilizing the A-ring of
dexamethasone [21]. We also examined the interaction of Gln
642
and Asn
564 with substituents on the D ring of dexamethasone.
Analysis of DBT in the allosteric site of the GR reveals van der
Waals contacts between DBT and Tyr
660, Tyr
663, Val
543, Leu
544
Figure 4. Dibutyltin abrogates GR-mediated suppression of cytokine production. Native human monocytes (A) or THP-1 cells (B) were
differentiated into macrophages, incubated for 16 h with various concentrations of DBT prior to the addition of LPS and dexamethasone. Cells were
incubated for another 20 h, and the levels of TNF-a (filled bars) and IL-6 (open bars) were determined by ELISA. Data represent mean6SD from three
independent experiments, normalized to the LPS-stimulated control.
doi:10.1371/journal.pone.0003545.g004
Figure 5. Inhibition of GR-mediated transrepression and
potentiation of TNF-a-induced activation of NF-kB. HEK-293
cells were transfected with a plasmid for a luciferase reporter gene
under the control of a promoter containing three NF-kB binding sites
together with a plasmid for human GR. Cells were preincubated for
16 h with various concentrations of DBT prior to stimulation with TNF-a
in the presence of glucocorticoids. Data represent mean6S.D. from
three independent experiments, normalized to the TNF-a -stimulated
control.
doi:10.1371/journal.pone.0003545.g005
Inhibition of GR by Dibutyltin
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611. There also is a coulombic interaction between Glu
540
and tin. Importantly, as shown in Figure 8A, there are two critical
steric clashes between dexamethasone and the GR in the
minimized GR-DBT complex. First, Gln
570 is 1.4 A ˚ from the
C3-ketone, and second, Gln
642 is 1.1 A ˚ from the C17 hydroxyl
group. Interestingly, other key amino acids, such as Asn
564, Arg
611
and Phe
623 [21], retain their favorable binding to dexamethasone.
Thus, the 3D-models indicate that binding of DBT to an allosteric
site in unliganded GR selectively distorts the ligand-binding
domain and alters the interaction with dexamethasone.
To determine if the ternary DBT-GR-dexamethasone complex
could relax into a conformation that would be favorable for
dexamethasone binding, we minimized this complex using Discover
3. Analysis of this complex (Fig. 8B) reveals that after energy
minimization the steric clashes between dexamethasone and Gln
570
and Gln
642 have been removed. After minimization, Gln
642 moved
to have a strong hydrogen bond with the C17 hydroxyl group, which
also is present in the GR crystal structure [21]. Gln
570 is more distant
from the C3ketone than in the crystal structure(Fig 7A).Thischange
may be due to a van der Waals contact between Gln
570 and DBT.
Figure 8B also shows that there are changes in other interactions
between DBT and residues in the allosteric pocket of the GR.
An important change, which has profound functional implica-
tions for steroid activation of the GR, is the loss of the contact
Figure 6. Docking sites for organotins in the GR. Autodock 4 was used to dock organotins (green) into the GR (1M2Z.pdb) (grey) without
dexamethasone. DBT (A) docked into two sites on GR, with the highest percentage in the dexamethasone-binding site (Table 1). The second site for
DBT was an adjacent allosteric pocket. Docking of TBT (B), DPT (C) and TPT (D) into the GR.
doi:10.1371/journal.pone.0003545.g006
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564 and the C11 hydroxyl on dexamethasone. Asn
564
and corresponding asparagines on the progesterone receptor (PR)
and mineralocorticoid receptor (MR) are important in stabilizing
binding and transcriptional activity of cognate steroids to these
receptors [22]. Asn
564 and Gln
570 are on a-helix 3 on the GR, PR
and MR. Arg
611 is on a-helix 5. The distance between a-helix 3
and a-helix 5 is crucial for steroid activation of the GR, PR [22]
and MR [23]. Our analysis indicates that DBT will alter the
conformation of a-helix 3 in the GR-dexamethasone complex.
Discussion
Despite the fact that organotins are well known and relevant
environmental pollutants, we are only beginning to understand their
mechanisms of toxicity. An important advance was the recent
observation that the triorganotins TBT and TPT are potent
activators of the nuclear hormone receptors RXR and PPARc
and that they promote adipocyte differentiation, suggesting that
these organotins might contribute to the development of metabolic
diseases[24–27].Interestingly,thediorganotinsDBT andDPTwere
found to be inactive toward RXR and PPARc in these studies.
Table 1. Relative calculated occupancy by organotins in the
GR.
Organotin Dexamethasone pocket Allosteric pocket
Dibutyltin 82% 18%
Tributyltin 100%
Diphenyltin 87% 13%
Triphenyltin 56% 44%
doi:10.1371/journal.pone.0003545.t001
Figure 7. Docking of organotins into the dexamethasone-binding site and at an allosteric site in the GR. A, DBT (white), TBT (blue), DPT
(orange) and TPT (yellow) fit into the dexamethasone-binding site of the GR. In these unminimized complexes with the GR, DBT and TBT overlap the
D-ring and DPT and TPT most of dexamethasone. Distances between dexamethasone and Gln
570, Arg
611, Asn
564 and Gln
642 are taken from the crystal
structure [21]. B, organotins docked into the GR at an allosteric site close to Glu
570 and Arg
611.
doi:10.1371/journal.pone.0003545.g007
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studied and understood. Here, we demonstrate for the first time
that DBT at nanomolar concentrations, but not other organotins
investigated, disrupts GR function. In a recent study we showed
that the organotins DBT, TBT, DPT and TPT inhibited the
enzyme 11b-HSD2, which catalyzes the conversion of active 11b-
hydroxyglucocorticoids into their inactive 11-keto derivatives [28].
IC50 values of 11b-HSD2 inhibition between 1 mM for TPT and
5 mM for DBT were obtained. Thus, while some organotins such
as TPT may enhance local glucocorticoid effects by inhibiting
11b-HSD2-dependent glucocorticoid inactivation, DBT blocks
GR activation at concentrations that are ten-fold lower than those
effective on 11b-HSD2. Importantly, 11b-HSD2 is not expressed
in HEK-293 and H4EII cells as well as THP-1 and native human
macrophages that are used in the present study, and the observed
effects of DBT are not caused by altered intracellular glucocor-
ticoid metabolism. These observations suggest that different
organotins cause distinct disturbances of corticosteroid hormone
action in vivo.
The ability of DBT to inhibit GR function is relevant for human
toxicity from two ways. First, humans are exposed to DBT
through its use as a heat stabilizer in the production of PVC plastic
materials (water distribution pipes, tubings and bottles) from which
it can leach into drinking water [9]. And second, DBT is likely to
be responsible for some of the toxicity of TBT in the environment,
because earlier in vivo studies indicated that trialkylated organotins
are mainly metabolized to their dialkylated forms by hepatic
cytochrome P450 enzymes through hydroxylation and deal-
kylation [29]. Ueno et al. showed that inhibition of hepatic
cytochrome P450 enzymes prevented TBT-dependent hepatotox-
icity [8], suggesting that hepatotoxicity is caused by its metabolites.
DBT was hardly degraded in the liver of treated mice, rats and
guinea pigs, indicating that the relatively inert DBT may be
responsible for some of the TBT toxicity observed in vivo.
Figure 8. Interactions of dibutyltin with the GR in an allosteric site close to the dexamethasone-binding site. A, After minimization of
the 3D-model of the DBT-GR complex, dexamethasone was inserted into the complex. There are steric clashes between dexamethasone and Gln
570
and Gln
642, which are absent in the GR crystal structure [21] (Fig. 7A). The distances of Asn
564, Arg
611 and Phe
623 to dexamethasone are similar to that
in the GR crystal structure. B, Interaction of dexamethasone with the GR after energy minimization of the DBT-GR-dexamethasone complex in (A) with
Discover 3. Gln
570 and Gln
642 have moved and no longer have steric clashes with dexamethasone. Asn
564, however, has moved to 4.5 A ˚ from the C11
hydroxyl on dexamethasone.
doi:10.1371/journal.pone.0003545.g008
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physiological processes including the control of energy metabolism
and the modulation of the immune system. Here, we demonstrate
that DBT blocks the glucocorticoid-induced expression of hepatic
PEPCK and TAT, two enzymes with a key role in energy
metabolism. Furthermore, our results from experiments with LPS-
stimulated native human macrophages and human THP-1
macrophages show that DBT is able to abolish the suppressive
effect of glucocorticoids on the synthesis of the pro-inflammatory
cytokines TNF-a and IL-6. By reducing the GR-dependent trans-
repression of NF-kB activation, DBT disrupts the anti-inflamma-
tory effect of glucocorticoids, which plays an important role for the
resolution of inflammatory reactions.
OurresultsindicatethatDBTdisruptsGR-mediatedregulationof
gene transcription at the initial step of receptor activation by
abolishing ligand binding to the receptor. The effects of DBT on
glucocorticoid-induced gene expression in liver cells and in
macrophages resembled those of RU486, supporting the evidence
that DBT directly inhibits GR activity. The concentrations of DBT
that affected GR-mediated gene expression in our experiments were
close to those found in tissue and blood samples from human and
wildlifeintherangeof3–300 nM[5,30–32].Moreover,weobserved
a more pronounced effect upon preincubation and after repeated
exposure of cells to medium containing DBT. The lipophilic
organotin molecules have been shown to accumulate near the lipid-
water interface of cellular membranes [33]. Thus, organotins may
reach higher concentrations in tissues, especially in those with high
lipid content, than in the circulation. A cellular accumulation is also
consistent with studies demonstrating up to 70,000 times higher
concentrations of organotins in plankton and other organisms
compared with sea water [34].
The GR-dependent effects of DBT on the LPS-induced
synthesis of TNF-a and IL-6 and the subsequent activation of
NF-kB found in the present study are in line with pro-
inflammatory effects of DBT and TBT previously reported [35–
37]. DBT as well as TBT which is metabolized in vivo to DBT,
induced inflammation of the bile duct associated with hepatic
lesions [35] and acute interstitial pancreatitis [36,37]. The present
study suggests that the exposure to DBT can interfere with
glucocorticoid-mediated modulation of the immune system and
may contribute to inflammatory diseases. DBT and other
chemicals disrupting glucocorticoid effects might contribute,
among other factors, to the high incidence of allergies and asthma
in developed countries [38].
Docking analysis of organotins into the GR 3D-structure
revealed that DBT, TBT DPT and TPT dock nicely into a site
overlapping the dexamethasone binding site, which would be
expected because these organotins are smaller than dexametha-
sone and should fit into this site. However, DBT and TBT have
fewer interactions with the GR than dexamethasone, DPT and
TBT. TBT, DPT and TPT did not inhibit GR-mediated
transactivation, suggesting that the inhibitory actions of DBT are
due to binding to an allosteric site. This hypothesis is supported by
DBT inhibition of GR-mediated transcriptional activity in the
presence of 100 nM cortisol, which is over ten-fold higher than the
Kd of cortisol for GR. At this concentration, the steroid binding
site on the GR will be occupied by cortisol.
Docking analysis identified a binding site for DBT close to
Gln
570 on a-helix 3 and Arg
611 on a-helix 5. DBT has several van
der Waals contacts with residues in this allosteric site on the GR.
Analysis of DBT in this site in the apo-GR and holo-GR reveals
that DBT alters the interaction of dexamethasone with the GR.
Analysis of the GR with DBT in the apo-GR revealed a
conformational change in the steroid binding pocket which results
in steric clashes between dexamethasone and Gln
570 and Gln
642
(Fig. 8A). Energy minimization of DBT in the holo-GR complex
removed these steric clashes. However, after energy minization,
Asn
564 moved and lost its stabilizing contact with the C11
hydroxyl on dexamethasone (Fig 8B). The interaction between a-
helix 3 and a-helix 5 is important in transcriptional activity of
steroids for the GR [22]. Alteration of a-helix 3 by DBT
occupying the allosteric site on the GR may explain how DBT
inhibits dexamethasone binding to GR and its subsequent
transcriptional activation.
Although neither TPT nor TBT altered GR-mediated tran-
scriptional activity in the absence of cortisol, both of these
organotins stimulated the activity of the GR-cortisol complex.
Binding of TPT and TBT to other proteins of the transcriptional
complex or effects on post-translational modifications of the
receptor or its associated proteins could be important in TBT- and
TPT-induced stimulation of GR-mediated transcription in the
presence of cortisol.
In conclusion, the present study demonstrates that DBT, but
not TBT, DPT or TPT, inhibits ligand binding to GR and
subsequent stimulation of its transcriptional activity. Molecular
modeling analyses indicate that binding to an allosteric site by
DBT, but not by the other organotins, alters the orientation of key
residues in the ligand binding pocket of the GR. Disruption of GR
activation by DBT can disturb essential physiological processes
such as the immune system, as shown by inhibition of
glucocorticoid-mediated suppression of pro-inflammatory cytokine
production in macrophages. Thus, by interfering with GR
function, DBT may contribute to immune diseases.
Materials and Methods
Analysis of transcriptional activation of reporter genes
HEK-293 cells were cultured in Dulbecco’s modified Eagle
medium (DMEM), supplemented with 10% fetal calf serum,
4.5 g/L glucose, 50 U/mL penicillin/streptomycin, 2 mM gluta-
mine, and 1 mM HEPES, pH 7.4. 200,000 cells/well were seeded
in poly-L-lysine coated 24-well plates, incubated for 16 h and
transfected by the calcium-phosphate method with plasmid for
human GR-a (0.1 mg/well), MMTV-lacZ b-galactosidase reporter
(0.15 mg/well) and pCMV-LUC luciferase transfection control
(0.05 mg/well). Cells were washed twice with serum- and steroid-
free DMEM 6 h later, followed by incubation for 16 h with
organotins. Cortisol (100 nM) was added and cells were incubated
for another 20 h. Cells were washed with PBS and lysed with 50 ml
lysis buffer (Tropix, Applied Biosystems, Foster City, CA)
supplemented with 0.5 mM dithiothreitol. 20 ml of lysate were
analyzed for b-galactosidase activity using the Tropix kit and
luciferase activity using a home-made luciferine-solution [39].
To measure NF-kB-dependent transcriptional activity, HEK-
293 cells were transfected with plasmid 3xMHCLUC (provided by
Dr. J. Cidlowski, [40]), containing three binding sites for NF-kBi n
the promoter preceding a luciferase gene, and a cytomegalovirus
(CMV)-driven galactosidase control plasmid to adjust for trans-
fection efficiency. The medium was exchanged by serum- and
steroid-free DMEM 6 h post-transfection, and cells were incubat-
ed overnight with DBT. Cells were stimulated by adding 5 nM
TNF-a with or without glucocorticoids or RU486, followed by
incubation for another 24 h. Thereafter, luciferase and galacto-
sidase activities were measured as described above.
Glucocorticoid receptor binding assay
HEK-293 cells (400,000 cells/well in 12-well plates) were
transfected with 0.2 mg/well GR plasmid, washed twice 6 h later
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medium overnight, followed by addition of vehicle (0.1% of
methanol or dimethylsulfoxide) or DBT, dexamethasone and
10 nM [
3H]-dexamethasone (specific activity 70 Ci/mmol).
Alternatively, cells were preincubated overnight with vehicle or
DBT prior to incubation with dexamethasone. After incubation
with dexamethasone for 3 h, cells were washed three times with
PBS, lysed with 300 ml of 0.4 N NaOH, and lysates were subjected
to scintillation counting. Non-specific binding was determined in
cells transfected with pcDNA3 control plasmid or in the presence
of 1 mM RU486 and subtracted from the values obtained in
absence of antagonist.
Glucocorticoid receptor expression analysis
HEK-293 cells transfected with GR plasmid were washed 6 h
later with serum- and steroid-free medium and incubated in this
medium for 16 h with vehicle control (0.1% DMSO), 10 nM
dexamethasone or 500 nM DBT. After preincubation, cells were
incubated for another 3 h in the presence of vehicle, 10 nM
dexamethasone or 500 nM DBT and 10 nM dexamethasone. In a
another sample, cells were preincubated overnight in serum-free
medium, followed by incubation for 3 h with 500 nM DBT and
10 nM dexamethasone. These conditions were chosen according
to the procedure used for GR ligand binding. GR protein was
detected by rabbit polyclonal anti-human GR antibody at a
working dilution of 1:500 (Santa Cruz, antibody sc-1030). Actin
served as a control to adjust for the amount of protein loaded on
the SDS-gel and was detected with a rabbit polyclonal antibody. A
horse-radish peroxidase conjugated mouse anti-rabbit antibody
was used as secondary antibody for detection.
Analysis of phosphoenolpyruvate carboxykinase (PEPCK)
mRNA levels
Rat H4EII hepatoma cells were cultured in MEM medium
containing 1 mM sodium pyruvate and supplemented with 10%
fetal calf serum, 4.5 g/L glucose, 50 U/mL penicillin/streptomy-
cin, 2 mM glutamine, and 1 mM HEPES, pH 7.4. H4EII cells
were preincubated for 16 h in serum-free MEM in the presence of
various concentrations of DBT or vehicle (dimethylsulfoxide),
followed by adding 10 nM dexamethasone and incubation for
another 24 h at 37uC. PEPCK mRNA expression was determined
by real-time RT-PCR as described earlier [41]. Briefly, total
mRNA was extracted from H4EII cells (500’000 cells per well)
using an mRNA isolation kit, and 100 ng of mRNA was reverse
transcribed using SuperscriptII reverse transcriptase according to
the manufacturer’s protocol (Invitrogen, Carlsbad CA). Relative
quantification of PEPCK mRNA expression levels was performed
on an ABI7600 Sequence Detection System (Applied Biosystems,
Foster City, CA). PCR reactions were performed in 96 well plates
using 25 ng of cDNA, TaqMan Universal PCR Master Mix and
assay on demand primers and probes from Applied Biosystems
(Mm01247057_g1) following the instructions from the manufac-
turer. The relative expression of each gene compared to the
internal control b-actin was determined using the 2-DCT method.
Determination of tyrosine aminotransferase (TAT) activity
H4IIE cells (300,000 cells/well in 6-wells plate) were allowed to
adhere overnight, and then washed twice with serum- and steroid-
free MEM followed by 16 h incubation with DBT. Dexametha-
sone (5 nM) was added, and cells were incubated for another 20 h,
washed once with PBS and lysed in lysis buffer (50 mM Tris-HCl,
pH 7.4, 50 mM NaCl, 0.2% Nonidet-P40) supplemented with
Complete Mini Protease Inhibitor cocktail at a working dilution of
1 tablet in 25 ml (Roche Applied Science, Rotkreuz, Switzerland).
After centrifugation (10 min, 10’0006g, 4uC), cleared lysates were
used to measure TAT activity. 50 ml of lysate (diluted in lysis-
buffer) was added to 465 ml of reaction mix (90 mM potassium-
phosphate buffer, pH 7.4, 25 mM L-tyrosine disodium, 90 mM a-
oxoglutarate, pH 7.0, 0.45 mM pyridoxal-59-phosphate, pH 6.5)
and incubated for 30 min at 37uC. The reaction was stopped by
adding 35 ml 10 N KOH, and after 30 min incubation at room-
temperature, the absorbance at 331 nm against a blank (lysis
buffer treated identically) was determined. The activity was
normalized to protein content in cell lysates, as determined by
BCA-solution (Pierce, Soccochim, Lausanne, Switzerland).
Analysis of cytokine production
THP-1 cells and native human monocytes (50,000 cells/well,
24-well plates) were grown in RPMI-1640 medium supplemented
with 10% FCS, 50 U/ml penicillin/streptomycin, 2 mM gluta-
mine and 25 mM HEPES, pH 7.4. Peripheral blood mononuclear
cells were purified from blood of non-smoking healthy male
volunteers of age 25–40 [42]. Venous EDTA-blood (180 ml) was
collected and left to sediment in 6% dextran. Leukocytes were
enriched for monocytes using a two-step discontinuous Percoll
gradient (1.0791 and 1.0695 g/ml). The purity of isolated
monocytes was 70–80%. Native human monocytes were differen-
tiated into macrophages by incubation for 7 days in culture
medium without medium change, whereas THP-1 cells were
differentiated by incubation with 5 ng/ml PMA for 72 h. The
medium was replaced by fresh RPMI-1640 containing DBT, and
cells were incubated for 16 h. Then, 10 nM dexamethasone and
30 ng/ml LPS were added and cells incubated for another 20 h
before harvesting the medium and analysis of IL-6 and TNF-a by
ELISA (BD Biosciences, Allschwil, Switzerland).
Docking of organotins within human GR
The PDB files for DBT, TBT, DPT and TPT were obtained
from CambridgeSoft’s Chemfinder chemical compound database.
Human GR (PDB:1M2Z) [21] was extracted from the PDB [43]
and converted into an apo-monomer using a text editor. Then,
organotins were docked into human GR using Autodock 4
[18,19]. The well depth and equilibrium separation for tin in DBT
and other organotins were set to 0.63 kJ/mol and 4.40 A ˚. Initially,
the grid size was set to cover the entire receptor. Lamarckian
Genetic Algorithm (LGA) docking was run for 100 trials of 25
million energy evaluations each and a histogram of the binding
energies for the various conformations was calculated [19]. This
analysis identified two interior sites in the GR. One site overlapped
the steroid-binding site. The other site was close to the A ring of
dexamethasone. Several non-specific sites for TPT and other
organotins were found on the surface of the GR. To analyze
docking of organotins to sites with a specific mode of binding, we
adjusted the grid to cover the interior of the GR and redid the
docking as described above.
The organotin-GR complex calculated by Autodock was refined
with Discover 3 software in Insight II, allowing the GR and the
organotin to move to an energy minimum. Discover 3 was used
with the ESSF force field and a distant dependent dielectric
constant of 2 for 10,000 iterations in each energy minimization.
Statistical analysis
Values are expressed as means6SD. Data were analyzed (and
significance assigned) using the ratio t-test in the GraphPad Prism
4 software. Data were also subjected to one- or two-way ANOVA
using SigmaStat software (Jandel Scientific, San Rafael, CA).
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